CDK8 and acute lymphoblastic leukemia: A small molecule that combines mTOR inhibition and degradation of CDK8 (YKL-06-101) induced cell death in human leukemic cells, representing a potential therapeutic strategy for treating acute lymphoblastic leukemia (ALL) patients.374